
Pooled analysis shows finerenone reduces all-cause mortality but not cardiovascular death
A pooled analysis of three large trials failed to demonstrate significant reductions in cardiovascular death with finerenone, but significantly lower all-cause mortality, cardiovascular events and kidney outcomes were observed, according to late-breaking research presented in a Hot Line session today at ESC Congress 2024.
Share
Facebook
X
LinkedIn
Telegram
Tumblr
Whatsapp
VK
Mail